Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: Its correlation to histologic findings in 43 cases

Modern Pathology

Volumn 13, Issue 1, 2000, Pages 13-18

  Moriya, Takuya ^a   Sakamoto, Kazuhiro ^b   Sasano, Hironobu ^a   Kawanaka, Miwa ^b   Sonoo, Hiroshi ^b   Manabe, Toshiaki ^b   Ito, Jishu ^b  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Apocrine carcinoma; Apocrine metaplasia; Breast; Immunohistochemistry; Ki 67; P53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; TUMOR MARKER;

ANTIGEN ANTIBODY COMPLEX; APOCRINE CARCINOMA; ARTICLE; BREAST CANCER; CANCER GRADING; CELL LABELING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MYOEPITHELIOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION;

EID: 0033980241     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880004     Document Type: Article

References (19)

1. Moriya T, Silverberg SG. Intraductal carcinoma of the breast. Int J Surg Pathol 1995;3:83-92.
2. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol 1994; 7:813-8.
3. O'Malley FP, Page DL, Nelson EH, Dupont WD. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum Pathol 1994;25:164-8.
4. Simpson JF, Page DL, Dupont WD. Apocrine adenosis: a mimic of mammary carcinoma. Surg Pathol 1990;3:289-99.
5. Carter DL, Rosen PP. Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients. Mod Pathol 1991;4:1-5.
6. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1996;5: 29-32.
7. Lininger RA, Tavassoli FA. Atypical intraductal hyperplasia of the breast. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins; 1997. pp. 195-222.
8. Silverberg SG, Masood S. The breast. In: Silverberg SG, Delellis RA, Frable WJ, editors. Principles and practice of surgical pathology and cytopathology. 3rd ed. New York: Churchill Livingstone; 1997. pp. 575-674.
9. Losi L, Lorenzini R, Eusebi V, Bussolati G. Apocrine differentiation in invasive carcinoma of the breast: comparison of monoclonal and polyclonal gross cystic disease fluid protein-15 antibodies with prolactin-inducible protein mRNA gene expression. Appl Immunohistochem 1995; 3:91-8.
10. Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma: a clinicopathologic study of 72 cases. Am J Clin Pathol 1990;94:371-7.
11. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA, et al. C-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 1992;52:2597-602.
12. Eriksson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer GU. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 1994; 25:1228-33.
13. Hoshi K, Tokunaga M, Mochizuki M, Ohtake T, Katagata N, Wakasa H, et al. Pathological characterization of atypical ductal hyperplasia of the breast (Japanese). Gan to Kagaku Ryoho 1995;22:S36-S41.
14. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL. P53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data. Lab Invest 1994;71:67-72.
15. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. P53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features and prognosis. J Clin Oncol 1995;13:821-30.
16. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesion of the breast: a long-term follow-up study. Cancer 1985;55:2698-708.
17. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer 1996;77:2529-37.
18. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, et al. P21 (Waf1/Kip1) and p53 protein expression in breast carcinoma. Am J Clin Pathol 1997;107:684-91.
19. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.